GSK's Arexvy Data: A Positive for the Vaccine, But the Market Is Already Priced for Perfection

The market has already priced in a permanent slowdown for adult RSV vaccines. The data from the fourth quarter of 2024 shows the harsh reality: U.S. sales of GSK's Arexvy and Pfizer's Abrysvo fell 69% and 62% year-over-year, respectively. The cause is clear and severe. Regulators narrowed the targeted age group for older adults, excluding millions who received a shot last year. This single policy change caused demand to fall by up to two-thirds.

The bottom line is a market that has been abruptly contracted. Both companies have been able to secure expanded approvals for younger age groups, but uptake depends on revised recommendations. For now, the adult market is in a deep freeze. The consensus view is that this is a structural shift, not a temporary dip. The market has digested this news, and the sharp sales declines were not entirely a surprise.

This sets the stage for new data. While the global RSV vaccine market is projected to grow from $1.1 billion in 2026 to $3.4 billion by 2034, that expansion is driven by infant and maternal segments, not the constrained adult market. The thesis here is that the adult segment's decline is already priced for perfection. Any positive data from GSK's latest studies is likely to be a minor positive, a slight beat on an already low bar, rather than a catalyst for a major re-rating. The competitive landscape has shrunk, and the market is focused on the next frontier, not the one that just disappeared.

The New Data: What's Priced In and What's Not

The new real-world data for Arexvy is strong, but it confirms what the market already knows. The study shows a 75.6% vaccine effectiveness against RSV-related hospitalization in adults over 60, a robust result that aligns with the 60–65% efficacy range seen in earlier clinical trials. It also adds valuable context by showing reductions in severe COPD and asthma flare-ups and a potential link to fewer major cardiovascular events during hospitalization.

From a clinical perspective, this is a positive reinforcement. It strengthens the case for Arexvy's protective profile in a vulnerable population. Yet, in the context of the adult RSV market, the data arrives at a time when the narrative has already shifted. The market has been priced for a permanent slowdown, not a new efficacy story. The sharp sales declines last year were driven by a regulatory contraction of the target age group, a structural issue that overshadows any single study's findings.

The key question is whether this data changes the risk/reward setup. For now, the answer appears to be no. The new numbers are a slight beat on an already low bar-the efficacy range was never in serious doubt. The real catalysts for a re-rating would be a policy reversal expanding the adult target group or a significant uptick in uptake for the younger, at-risk cohort. Until then, the data is more of a footnote confirming the vaccine's quality than a signal that the market's pessimistic view is wrong.

The bottom line is one of expectations gap. The market has digested the bad news about demand. It is now focused on the next frontier: infant and maternal vaccines. The new Arexvy data, while solid, does not alter the fundamental constraint in the adult segment. It is priced for perfection, and this result is simply the baseline.

Competitive Positioning and Financial Impact

GSK's position is one of dominance in a shrinking arena. The company holds a 9 million American vaccinated with Arexvy, representing a two-thirds market share in the first RSV season. Yet this lead is under pressure. Pfizer is gaining share, and the competitive dynamic has fundamentally shifted. While GSK was first to market, Pfizer now holds a key advantage with its maternal vaccine Abrysvo, which protects infants-a separate and growing segment. This maternal indication provides Pfizer with a durable, recurring demand stream that GSK's adult-focused Arexvy lacks.

The financial impact of the new efficacy data is therefore constrained. The market's reaction is likely to be muted because the core demand problem remains unchanged. The structural headwinds-narrowed U.S. guidelines and a one-time shot recommendation-have already been priced in. Sales of both vaccines fell sharply last quarter, with Arexvy sales declining 69% year-over-year. The new data does not address these regulatory and behavioral frictions. It confirms Arexvy's clinical profile but does nothing to expand the target population or alter the vaccination schedule.

Viewed another way, the data reinforces GSK's quality but highlights its vulnerability. The company's financial exposure is tied to a market that regulators have contracted. Pfizer, by contrast, has a dual franchise. Its maternal vaccine Abrysvo saw strong demand last quarter, partially offsetting its adult sales decline. This diversification provides a more stable financial foundation. For GSK, the path to growth now hinges on the younger, at-risk adult cohort and global markets, areas where uptake depends on future guidance and may face slower ramp-up.

The bottom line is a setup where expectations are low. The market has already adjusted to a permanent slowdown in adult RSV sales. Any positive data is a slight beat on an already depressed baseline. The real financial impact will come from the next frontier-infant and maternal vaccines-where the competitive race is just beginning. For now, the adult segment is a story of market share battles in a fixed pie, not a catalyst for a major re-rating.

Risk/Reward Asymmetry and What to Watch

The risk/reward setup for GSK's RSV franchise is now asymmetrical. The overwhelming headwinds are already priced in, leaving the stock vulnerable to further disappointment if the new data fails to drive a meaningful rebound. The key risk is that the market's low expectations are met, but not exceeded. With sales of Arexvy down 69% year-over-year last quarter due to a more limited recommendation for individuals aged 60 to 74, the negative growth trajectory is the baseline. Any positive data, while clinically supportive, is unlikely to alter the fundamental demand equation in the U.S. adult market.

The forward-looking catalysts that could change the thesis are narrow and hinge on policy or clinical breakthroughs. First, watch for any shift in U.S. guidelines that could expand the recommended age group beyond the current 60-74 cohort at increased risk. The data for adults aged 75 and older is strong, with a pooled efficacy estimate of 69.4% in clinical trials. If regulators recommend vaccination for all adults over 75, it could unlock a significant new population. Second, monitor GSK's R&D progress in respiratory medicines. The company has signaled a plan to increase and prioritize R&D investment in this category, which could indicate a strategic pivot away from the constrained adult RSV market toward new indications or next-generation products.

In practice, the market is likely to remain focused on the next frontier. The real catalysts for a re-rating are not in the adult segment but in infant and maternal vaccines, where Pfizer already holds a dual advantage. For now, the risk/reward favors caution. The downside-the continuation of the current sales decline-is already reflected in the stock. The upside requires a major policy reversal or a clinical breakthrough that expands the addressable market. Until then, the new Arexvy data is a minor positive, a slight beat on an already low bar.